Abstract:BackgroundTakayasu’s arteritis (TAK) is a chronic, non-specific, granulomatous macrovasculitis and its pathogenesis is still unclear. The increasing evidence indicated that multiple pathological process involved in the development of TAK. According to previous reports, multiple biomarkers representative different pathological process (1-3), However, which biomarker can closely reflect disease activity or vascular changes and whether these abnormal processes can be prevented by current therapies remained unknown.ObjectivesTo analyze changes of serum cytokine, chemokine, and growth factor profiles in patients with Takayasu arteritis (TAK) after tofacitinib treatment and explore potential molecular signatures related with various disease characteristicsMethodsSeventeen patients from a TAK cohort treated with tofacitinib and 12 healthy controls were recruited in this study. Potential biomarkers with TAK including cytokines, MMPs, chemokines and growth factors were detected in these patients (0, 6, 12 months) and healthy controls. Molecular changes, disease activity, disease remission, and vascular imaging changes were analyzed in these patients after treatment. Furthermore, molecule signatures associated with these clinical features/outcomes were explored via radar plot and correlation analysis.ResultsAt baseline, all the patients were in active status. Meanwhile, patients’ cytokines (PTX3, IL-6, IFN-γ), chemokines (IL-16, CCL22, CCL2), growth factor (VEGF) and MMP9 were significantly higher than those of healthy controls (all p<0.05), while FGF-2 was significantly lower in patients with TAK (p=0.02). After treatment, 94.12% of patients achieved complete remission at 6 and 12 months; patients’ ESR and CRP levels were significantly reduced at 6 months (p=0.02, p=0.046 respectively); vascular improvement were observed in 6 (35.29%) patients at 12 months. With regards to these molecules, IL-10 was increased at 6 months compared with its baseline level (p=0.007). No changes were observed in other cytokines, chemokines, or growth factors. Besides, the radar plot demonstrated that PTX3 was closely correlated with disease activity. In addition, patients with vascular imaging improvement had relatively higher baseline levels of TNFα, ESR, and CRP (p=0.04, p=0.056, p=0.07, respectively), lower CCL22, FGF, and PDGF-AB levels (p=0.056, p=0.06 and p=0.08 respectively) compared with patients without it.ConclusionMultiple molecules representative different pathological mechanism participated in the pathogenesis of TAK. PTX3 was a prominent marker for disease activity, and CCL22 may have a predictive value for vascular imaging changes.References[1]Dagna L, Salvo F, Tiraboschi M, et al. Pentraxin-3 as a marker of disease activity in Takayasu arteritis. Ann Intern Med. 2011;155(7):425-433. doi:10.7326/0003-4819-155-7-201110040-00005[2]Sun Y, Kong X, Wu S, et al. YKL-40 as a new biomarker of disease activity in Takayasu arteritis. Int J Cardiol. 2019; 293: 231-237[3]Dong H, Zhang Y, Zou Y, et al. Elevated chemokines concentration is associated with disease activity in Takayasu arteritis. Cytokine. 2021; 143: 155515Disclosure of InterestsNone declared

Alterations of Gut Microbiome, Metabolome, and Lipidome in Takayasu Arteritis.

Exploration of Molecular Signatures Associated with Different Clinical Features of Takayasu Arteritis Based on a Prospective Cohort Study.

POS0799 BIOMARKER CHANGES IN TAKAYASU ARTERITIS AFTER TOFACITINIB TREATMENT AND THE MOLECULAR SIGNATURE ASSOCIATED WITH DISEASE CHARACTERISTICS

A COMPREHENSIVE PROFILE OF CHEMOKINES IN THE PERIPHERAL BLOOD AND VASCULAR TISSUE OF PATIENTS WITH TAKAYASU ARTERITIS

High-throughput sequencing reveals the change of TCR α chain CDR3 with Takayasu arteritis

Identification of the Association Between Toll-Like Receptors and T-Cell Activation in Takayasu's Arteritis

Identification of the Association Between Toll-Like Receptors and T-Cell Activation in Takayasu’s Arteritis

The Critical Role of IL-6 in the Pathogenesis of Takayasu Arteritis.

Biomarker Changes and Molecular Signatures Associated with Takayasu Arteritis Following Treatment with Glucocorticoids and Tofacitinib

Dysregulation of long non-coding RNAs in Takayasu arteritis: A proof-of-concept study

Identification of Susceptibility Loci for Takayasu Arteritis Through a Large Multi-Ancestral Genome-Wide Association Study

Gut microbiome and metabolome to discover pathogenic bacteria and probiotics in ankylosing spondylitis

Risk factors for the adverse cardiac outcomes in the patients with Takayasu’s arteritis.

Characteristics of B Cells and Immunoglobulin Profile in Takayasu's Arteritis

Novel Th17 Lymphocyte Populations, Th17.1 and PD1+Th17, are Increased in Takayasu Arteritis, and Both Th17 and Th17.1 Sub-Populations Associate with Active Disease

A Glimpse into Humoral Response and Related Therapeutic Approaches of Takayasu's Arteritis

Alterations in the Gut Microbiome and Metabolism with Coronary Artery Disease Severity.

Coronary artery calcification in Takayasu's arteritis: clinical characteristics and risk factors

Curcumin Alleviates Inflammation in Takayasu's Arteritis by Blocking CCL2 Overexpression in Adventitial Fibroblasts

The Gut Microbiome and Metabolites Are Altered and Interrelated in Patients With Rheumatoid Arthritis

Alterations of the Gut Microbiome and TMAO Levels in Patients with Ulcerative Colitis